Your browser doesn't support javascript.
loading
Transforming ovarian cancer care by targeting minimal residual disease.
Jazaeri, Amir A; Grisham, Rachel; Knisely, Anne; Spranger, Stefani; Zamarin, Dmitriy; Hillman, R Tyler; Lawson, Barrett C; Burns, Kathleen H; Lee, Sanghoon; Westin, Shannon N; Moiso, Enrico; Williams, Marc J; Bardhan, Neelkanth M; Pisanic, Thomas; Matulonis, Ursula; Weigelt, Britta; Shih, IeMing; Konstantinopoulos, Panagiotis A; Gaillard, Stephanie; Wang, Linghua; Aghajanian, Carol; D'Andrea, Alan D; Hammond, Paula; Shah, Sohrab; Wucherpfennig, Kai W; Lu, Karen H.
Afiliación
  • Jazaeri AA; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aajazaeri@mdanderson.org.
  • Grisham R; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Knisely A; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spranger S; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Zamarin D; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hillman RT; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lawson BC; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Burns KH; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lee S; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin SN; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Moiso E; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Williams MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bardhan NM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Break Through Cancer, Cambridge, MA, USA.
  • Pisanic T; Break Through Cancer, Cambridge, MA, USA.
  • Matulonis U; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Weigelt B; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shih I; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Konstantinopoulos PA; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gaillard S; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Wang L; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Aghajanian C; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • D'Andrea AD; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hammond P; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Shah S; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wucherpfennig KW; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lu KH; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Med ; 4(11): 755-760, 2023 11 10.
Article en En | MEDLINE | ID: mdl-37951209
ABSTRACT
Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas Límite: Female / Humans Idioma: En Revista: Med Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas Límite: Female / Humans Idioma: En Revista: Med Año: 2023 Tipo del documento: Article